Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC

Go back to Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC

Cowen Reiterates Outperform on Celgene (CELG) Following a Soft 3Q

November 5, 2015 3:40 PM EST

Cowen reiterated an Outperform rating and $150.00 price target on Celgene (NASDAQ: CELG), following the company's 3Q earnings report. Celgene reported non-GAAP EPS of $1.23, slightly beating consensus of $1.21. Revenues of $2.33B compared to consensus of $2.39B. TThe 18% growth in product sales was driven... More

Celgene (CELG) Tops Q3 EPS by 2c; Guides In-Line

November 5, 2015 7:34 AM EST

Celgene (NASDAQ: CELG) reported Q3 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.4 billion.

"Our strong third quarter performance and acceleration of key drivers create significant momentum in our business, further... More